Patent ID: 9493560
Filing Date: 2016-11-15
CPC Classification: A61K,A61P,C07K,G01N

Claim Text:
1. A method for treating a subject for a disease or a disorder in which the activity of IL-17 is detrimental, comprising administering to the subject a binding protein comprising first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C-(X2)n, wherein VD1 is a first variable domain; VD2 is a second variable domain; C is a constant domain; X1 is a linker; X2 is an Fc region; n is 0 or 1; wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site, (a) wherein the binding protein is capable of binding IL-17, and wherein the variable domains that form a functional target binding site for IL-17 comprise CDRs 1-3 from SEQ ID NO: 40 and CDRs 1-3 from SEQ ID NO: 41; (b) wherein the binding protein is also capable of binding IL-1β or TNFα; and (c) wherein the disease or disorder is selected from the group consisting of rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, septic arthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy, spondilitis anklyosans, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, inflammatory bowel disease, psoriasis, sarcoidosis, uveitis, atopic eczema, scleroderma, and amyotrophic lateral sclerosis.